Bacteriostatic - Bactericidal;Bakteriostase - Bakterizidie

Medizinische Klinik

Volumn 102, Issue 9, 2007, Pages 720-726

  Heizmann, Petra ^a   Heizmann, Wolfgang R ^b  

^a Klinik St Wolfgang   (Germany)

^b Zentrum für Mikrobiologie und Infektiologie   (Germany)

Author keywords

Antimicrobial agent; Bactericidal; Bacteriostatic; Infection; Therapy comparison

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CARBAPENEM DERIVATIVE; CEFTRIAXONE; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; IMIPENEM; LINEZOLID; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; PIPERACILLIN; QUINOLONE DERIVATIVE; RIFAMPICIN; SULFONAMIDE; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CLINICAL TRIAL; CLOSTRIDIUM PERFRINGENS; COLONY FORMING UNIT; DOSE RESPONSE; DRUG HALF LIFE; ENDOCARDITIS; ENTEROBACTERIACEAE; HAEMOPHILUS INFLUENZAE TYPE A; HUMAN; IMMUNE RESPONSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONTE CARLO METHOD; NEISSERIA MENINGITIDIS; NONHUMAN; REVIEW; STREPTOCOCCUS PNEUMONIA;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRACYCLINE; TREATMENT OUTCOME;

EID: 34648819269     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-007-1090-8     Document Type: Review

References (45)

1. Babinchak T, Ellis-Grosse E, Dartois N, et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005;41: Suppl 5:S354-67.
2. Baracco GJ, Bisno AL. Therapeutic approaches to streptococcal toxic shock syndrome. Curr Infect Dis Rep 1999;1:230-7.
3. Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005;56:128-32.
4. Davidson R, Cavalcanti R, Brunton JL, et al. Brief report: Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747-50.
5. De Feiter PW, Jacobs JA, Jacobs MJ, et al. Successful treatment of Staphylococcus epidermidis prosthetic valve endocarditis with linezolid after failure of treatment with oxacillin, gentamicin, rifampicin, vancomycin, and fusidic acid regimens. Scand J Infect Dis 2005;37:173-6.
6. Del Favero A, Menichetti F, Martino P, et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001:33:1295-301.
7. Donowitz GR, Maki DG, Crnich CJ, et al. Infections in the neutropenic patient - new views of an old problem. Hematology Am Soc Hematol Educ Program 2001:113-39.
8. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41:Suppl 5:S341-53.
9. Falagas ME, Manta KG, Ntziora F, et al. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 2006;58:273-80.
10. Feder HM Jr. Chloramphenicol: what we have learned in the last decade. South Med J 1986;79:1129-34.
11. Fowler VG Jr, Bocher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-65.
12. Geraci JE, Martin WJ. Antibiotic therapy of bacterial endocarditis: IV. Subacute enterococcal endocarditis: clinical, pathologic and therapeutic consideration of 33 cases. Circulation 1954;10:173-94.
13. Grandel U, Hopf M, Buerke M, et al. Mechanisms of cardiac depression caused by lipoteichoic acids from Staphylococcus aureus in isolated rat hearts. Circulation 2005;112:691-8.
14. Hattar K, Grandel U, Moeller A, et al. Lipoteichoic acid (LTA) from Staphylococcus aureus stimulates human neutrophil cytokine release by a CD14-dependent, Toll-like-receptor-independent mechanism: autocrine role of tumor necrosis factor-[alpha] in mediating LTA-induced interleukin-8 generation. Crit Care Med 2006;34:835-41.
15. Jaccard C, Troillet N, Harbarth S, et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998;42:2966-72.
16. Kishi K, Hirai K, Hiramatsu K, et al. Clindamycin suppresses endotoxin released by ceftazidime-treated Escherichia coli O55:B5 and subsequent production of tumor necrosis factor alpha and interleukin-1 beta. Antimicrob Agents Chemother 1999;43:616-22.
17. Knothe H, Shah P, Krcmery V, et al. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983;11:315-7.
18. Koeth LM, Good CE, Saunders KA, et al. Streptococcus pneumoniae in vitro development of resistance to amoxicillin/clavulanic acid, cefaclor, levofloxacin and azithromycin. Int J Antimicrob Agents 2004;24:144-9.
19. Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004;30:388-94.
20. König C, Stimmen HP, Blaser J. Bacterial concentrations in pus and infected peritoneal fluid - implications for bactericidal activity of antibiotics. J Antimicrob Agents 1998;42:227-32.
21. Kotb M. Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev 1995;8:411-26.
22. La Plante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004;48:4665-72.
23. Li Y, Karlin A, Loike JD, et al. A critical concentration of neutrophils is required for effective bacterial killing in suspension. Proc Natl Acad Sci U S A 2002;99:8289-94.
24. Lowdin E, Cars O, Odenholt I. Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens including a pharmacokinetically enhanced formulation. Clin Microbiol Infect 2002;8:646-53.
25. Mathies AW Jr, Leedom JM, Ivler D, et al. Antibiotic antagonism in bacterial meningitis. Antimicrob Agents Chemother 1967;7:218-24.
26. Moczygemba LR, Frei CR, Burgess DS. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. Clin Ther 2004;26:1800-7.
27. Musher DM, Dowell ME, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococal pneumonia. N Engl J Med 2002;346:630-1.
28. Olofsson SK, Geli P, Andersson DI, et al. Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli. Antimicrob Agents Chemother 2005;49:5081-91.
29. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis 2004;38:864-7.
30. Pizzo PA. Management of fever in patients with cancer and treatment induced neutropenia. N Engl J Med 1993;328:1323-32.
31. Rahal JJ Jr, Simberkoff MS. Bactericidal and bacteriostatic action of chloramphenicol against meningeal pathogens. Antimicrob Agents Chemother 1979;16:13-8.
32. Retsema J, Girard A, Schelkly W, et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother 1987;31:1939-47.
33. Rodriguez-Bano J, Navarro MD, Romero L, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004;42:1089-94.
34. Salvatore CM, Katz-Gaynor K, McCracken GH, et al. Tigecycline therapy significantly reduces inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia. Presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 2006.Poster B-401.
35. Sevillano D, Alou L, Aguilar L, et al. Azithromycin iv pharmacodynamic parameters predicting Streptococcus pneumoniae killing in epithelial lining fluid versus serum: an in vitro pharmacodynamic simulation. J Antimicrob Chemother 2006;57:1128-33.
36. Stevens DL, Maier KA, Mitten JE. Effect of antibiotics on toxin production and viability of Clostridium perfringens. Antimicrob Agents Chemother 1987;31:213-8.
37. Stevens DL, Yan S, Bryant AE. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis 1993;167:1401-5.
38. Stratton CW. Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis 2003;9:10-6.
39. Szabo D, Bonomo RA, Silveira F, et al. SHV-type extended-spectrum beta-lactamase production is associated with reduced cefepime susceptibility in Enterobacter cloacae. J Clin Microbiol 2005;43:5058-64.
40. Tanaka M, Hasegawa T, Okamoto A, et al. Effect of antibiotics on group A Streptococcus exoprotein production analyzed by two-dimensional gel electrophoresis. Antimicrob Agents Chemother 2005;49:88-96.
41. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998;42:521-7.
42. Wang AL, Yu AC, Lau LT, et al. Minocycline inhibits LPS-induced retinal microglia activation. Neurochem Int 2005;47:152-8.
43. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260-6.
44. Wu TL, Chia JH, Su LH, et al. Dissemination of extended-spectrum beta-lactamase-producing Enterobacteriaceae in pediatric intensive care units. J Clin Microbiol 2003;41:4836-8.
45. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996;40:839-45.